Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What...

por Frechen, Sebastian, Rostami-Hodjegan, Amin
Publicado 2022

1st Graph Theory Conference

por Capobianco, M, Frechen, Joseph B, Krolik, Max
Publicado 1971

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone

por Wendl, Thomas, Frechen, Sebastian, Gerisch, Michael, Heinig, Roland, Eissing, Thomas
Publicado 2021

Inflammatory parameters and prediction of prognosis in infective endocarditis

por Cornelissen, Christian G, Frechen, Dirk A, Schreiner, Karin, Marx, Nikolaus, Krüger, Stefan
Publicado 2013

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

por Hanke, Nina, Frechen, Sebastian, Moj, Daniel, Britz, Hannah, Eissing, Thomas, Wendl, Thomas, Lehr, Thorsten
Publicado 2018

Ice-volume-forced erosion of the Chinese Loess Plateau global Quaternary stratotype site

por Stevens, T., Buylaert, J.-P., Thiel, C., Újvári, G., Yi, S., Murray, A. S., Frechen, M., Lu, H.
Publicado 2018

Knowledge Mapping for Climate Change and Food- and Waterborne Diseases

por Semenza, Jan C., Höuser, Christoph, Herbst, Susanne, Rechenburg, Andrea, Suk, Jonathan E., Frechen, Tobias, Kistemann, Thomas
Publicado 2011

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pio...

por Türk, Denise, Hanke, Nina, Wolf, Sarah, Frechen, Sebastian, Eissing, Thomas, Wendl, Thomas, Schwab, Matthias, Lehr, Thorsten
Publicado 2019

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interact...

por Frechen, Sebastian, Solodenko, Juri, Wendl, Thomas, Dallmann, André, Ince, Ibrahim, Lehr, Thorsten, Lippert, Jörg, Burghaus, Rolf
Publicado 2021

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam

por Britz, Hannah, Hanke, Nina, Volz, Anke‐Katrin, Spigset, Olav, Schwab, Matthias, Eissing, Thomas, Wendl, Thomas, Frechen, Sebastian, Lehr, Thorsten
Publicado 2019

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children

por Ince, Ibrahim, Dallmann, André, Frechen, Sebastian, Coboeken, Katrin, Niederalt, Christoph, Wendl, Thomas, Block, Michael, Meyer, Michaela, Eissing, Thomas, Burghaus, Rolf, Lippert, Jörg, Willmann, Stefan, Schlender, Jan‐Frederik
Publicado 2021

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions

por Loer, Helena Leonie Hanae, Feick, Denise, Rüdesheim, Simeon, Selzer, Dominik, Schwab, Matthias, Teutonico, Donato, Frechen, Sebastian, van der Lee, Maaike, Moes, Dirk Jan A. R., Swen, Jesse J., Lehr, Thorsten
Publicado 2023

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network

por Feick, Denise, Rüdesheim, Simeon, Marok, Fatima Zahra, Selzer, Dominik, Loer, Helena Leonie Hanae, Teutonico, Donato, Frechen, Sebastian, van der Lee, Maaike, Moes, Dirk Jan A. R., Swen, Jesse J., Schwab, Matthias, Lehr, Thorsten
Publicado 2023

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

por Lippert, Jörg, Burghaus, Rolf, Edginton, Andrea, Frechen, Sebastian, Karlsson, Mats, Kovar, Andreas, Lehr, Thorsten, Milligan, Peter, Nock, Valerie, Ramusovic, Sergej, Riggs, Matthew, Schaller, Stephan, Schlender, Jan, Schmidt, Stephan, Sevestre, Michaël, Sjögren, Erik, Solodenko, Juri, Staab, Alexander, Teutonico, Donato
Publicado 2019

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

por Nogova, Lucia, Mattonet, Christian, Scheffler, Matthias, Taubert, Max, Gardizi, Masyar, Sos, Martin L., Michels, Sebastian, Fischer, Rieke N., Limburg, Meike, Abdulla, Diana S.Y., Persigehl, Thorsten, Kobe, Carsten, Merkelbach‐Bruse, Sabine, Franklin, Jeremy, Backes, Heiko, Schnell, Roland, Behringer, Dirk, Kaminsky, Britta, Eichstaedt, Martina, Stelzer, Christoph, Kinzig, Martina, Sörgel, Fritz, Tian, Yingying, Junge, Lisa, Suleiman, Ahmed A., Frechen, Sebastian, Rokitta, Dennis, Ouyang, Dongsheng, Fuhr, Uwe, Buettner, Reinhard, Wolf, Jürgen
Publicado 2020